this condition. The immobilization was checked by means of imaging studies performed both pre-and postoperatively; however, in all cases, a stenopeic disc was fixed to the eyeball to be treated.
Leksell GammaPlan (version 5.31; Elekta Instrument AB, Stockholm, Sweden) planning system was used for dose planning. The relevant muscular thickening was defined as the target. The dose indicated for the lesion margin was 6.5 Gy placed on the 50% isodose line at a maximum dose of 13 Gy. The mean dose delivered was 8.5 Ϯ 2.1 Gy. In no case was the dose delivered to the optic nerve higher than 4 Gy. For the unilateral lesions 22, 20, 17, and 15 isocenters were used and 32 for the bilateral treatment ( Fig.   1 ). In all cases, some plugging was used to adapt the radiation volume to the target volume (Fig. 2) . The mean target volume was 1.3 cm 3 (range 0.5-3.6 cm 3 ). During the 2-year follow up, all the patients were clinically evaluated by a neurosurgeon and an ophthalmologist on a weekly basis during the first 2 months and then every 30 days during the 1st year. After the 1st year, control evaluations were performed every 3 months until the end of the study. Imaging studies were performed within 30 days of the procedure and then every 4 months during the 1st year. Another control evaluation was performed at the end of the study. 
Results
Even at the first clinical evaluation 1 week after the procedure, symptoms and acute inflammatory signs had improved. Also, decreases in chemosis, conjunctival edema, and photophobia were observed in all the patients. The intraocular foreign body sensation disappeared and was the symptom with the best improvement recorded. During the period between 60 and 90 days after GKS, images revealed a decrease in the volume of the muscles treated. Consequently, on clinical evaluation an improvement in proptosis was observed, which was considered a 2-mm or greater decrease by using the Hertel method. Recovery of visual acuity then followed, and intraocular pressure went down. The decrease in proptosis and intraocular pressure was associated with an improvement in lacrimation. Severe ophthalmoplegia with manifest strabismus with a long symptomatic history showed the least improvement, occurring in only one patient (20%). All the results obtained during the 1st year were maintained until the end of the follow-up period. No side effects due to radiation were observed. It would seem that GKS is precise enough and safe enough at an apparently biologically effective dose to spare surrounding tissues (Figs. 3-7) .
Discussion
According to the theory of Topliss and Volpe, 8 abnormal clonal proliferation of plasma cells is not prevented by abnormal and malfunctioning suppressor T lymphocytes. A consequence of this proliferation could be migration of abnormal plasma cells to the orbit, with the production of antibodies that form antigen-antibody complexes, coating the extraocular muscle fibers with a secondary inflammatory reaction. The resulting muscle enlargement could lead to congestion of the orbital contents and promote the symptoms described. The radiobiological effectiveness of a low dose of radiation would not be surprising in view of the influence of radiation on both T-cell subsets and fibroblasts. The inactivation of T cells and other mediator cells stimulates antiinflammatory activity by reducing the number of lymphocytes and normalizing pH levels. When exposed to radiation, fibroblasts exhibit a decrease in their activity and also a decrease in glycosaminoglycan release, resulting in an antiedematous action. All this has been clearly shown in several studies, which reported successful results in the use of fractionated external-beam radiation. The risk factors leading to the development of ophthalmopathies in Graves disease have been investigated in recent years, mainly in relation to the different treatment modalities used in thyrotoxicosis. Tallstedt and coworkers 7 reported a significant increase in the risk of ophthalmopathy development or worsening of existing ophthalmopathies in patients treated with radioiodine compared with those treated surgically and with antithyroid agents. One hundred seventy-nine patients were included in their study: 13% of those treated surgically or with antithyroid agents and 33% of those treated with radioiodine therapy either developed ophthalmopathy or their existing ophthalmopathies grew worse.
In brief, although ophthalmopathy seems to be independent of the thyroid status and can occur in euthyroid patients, there is enough evidence to show that it is more likely to occur in patients who develop hypothyroidism after undergoing radioiodine therapy.
This small study indicates that GKS may well be more effective and could have a more significant impact during the early and inflammatory stages of the disease, considering that in cases of severe ophthalmoplegia corrective surgery may be required.
Conclusions
It appears that GKS has had a beneficial clinical effect on the ophthalmopathy in Graves disease in six eyes in five patients, all of which had severe disease. There were no regressions of beneficial effect nor GKS-related complications in a follow-up period of 2 years. The effect on severe well established ophthalmoplegia was disappointing so that the treatment might work even better at an earlier stage of the disease.
